Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (51,287)	$ (24,416)	$ (19,434)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization expense	6,196	5,848	5,072
Stock-based compensation expense	24,096	28,986	30,020
Loss on sale of health assets	19,388
Impairment of right-of-use asset	384
Change in fair value of contingent consideration liabilities	(150)	(4,135)	196
Deferred taxes			(2,510)
Provision for (recovery of) bad debt	204	693	(41)
Unrealized foreign currency transaction (gains) losses	21	(9)	24
Changes in operating assets and liabilities, net of effects from acquisition:
Accounts receivable	8,219	5,362	10,511
Prepaid expenses and other current assets	962	(2,111)	1,801
Commissions receivable, current and non-current	4,176	(24,240)	(16,871)
Operating lease right-of-use assets	2,497	2,613	2,710
Other assets	421	(19)	534
Accounts payable	(13,411)	1,124	(3,968)
Accrued expenses and other current liabilities	(1,543)	(2,375)	2,692
Deferred revenue	5	(229)	227
Operating lease liabilities	(3,006)	(2,883)	(2,840)
Other long-term liabilities			(934)
Net cash provided by (used in) operating activities	(2,828)	(15,791)	7,189
Cash flows from investing activities:
Acquisition of property and equipment, including costs capitalized for development of internal-use software	(3,840)	(4,290)	(2,862)
Proceeds from sale of health assets	13,194
Acquisition of business			(15,955)
Net cash provided by (used in) investing activities	9,354	(4,290)	(18,817)
Cash flows from financing activities:
Proceeds from exercise of stock options	979	942	3,615
Proceeds from private placement of common stock		15,000
Tax withholding payments related to net share settlement	(402)	(100)
Net cash provided by financing activities	577	15,842	3,615
Effect of exchange rate changes on cash, cash equivalents and restricted cash	18	(27)	(6)
Net increase (decrease) in cash, cash equivalents and restricted cash	7,121	(4,266)	(8,019)
Cash, cash equivalents and restricted cash at beginning of period	30,835	35,101	43,120
Cash, cash equivalents and restricted cash at end of period	37,956	30,835	35,101
Supplemental disclosure of noncash investing and financing information:
Acquisition of property and equipment included in accounts payable	25	60	100
Fair value of contingent consideration in connection with acquisition included in liabilities			3,784
Operating lease liabilities arising from obtaining right-of-use assets		1,096	383
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	37,956	30,835	34,851
Restricted cash (included in other assets)			250
Cash, cash equivalents and restricted cash at end of period	$ 37,956	30,835	$ 35,101
Settle Contingent Consideration Liability
Supplemental disclosure of noncash investing and financing information:
Issuance of Class A common stock		1,889
Settlement of Stock-Based Compensation Liability
Supplemental disclosure of noncash investing and financing information:
Issuance of Class A common stock		$ 164